{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:31:04Z","timestamp":1770471064351,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12012-025-10059-7","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:01:13Z","timestamp":1758297673000},"page":"1754-1760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hormone Receptor Expression and QT interval at Baseline Correlate with Trastuzumab Associated Cardiotoxicity in HER2- Positive\nBreast Cancer Patients: A Prospective Study"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-2634","authenticated-orcid":false,"given":"Dana","family":"Abo Samra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5306-0128","authenticated-orcid":false,"given":"Ibrahem","family":"Hanafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani","family":"Abo Samra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assef","family":"Dayyoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"10059_CR1","unstructured":"Alkabban FM, Ferguson T. Breast Cancer. [Updated 2021 Aug 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482286\/"},{"issue":"1","key":"10059_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019). Breast cancer. Nature Reviews Disease Primers, 5(1), Article 66. https:\/\/doi.org\/10.1038\/s41572-019-0111-2","journal-title":"Nature Reviews Disease Primers"},{"issue":"11","key":"10059_CR3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.7150\/ijbs.21635","volume":"13","author":"YS Sun","year":"2017","unstructured":"Sun, Y. S., Zhao, Z., Yang, Z. N., Xu, F., Lu, H. J., Zhu, Z. Y., Shi, W., Jiang, J., Yao, P. P., & Zhu, H. P. (2017). Risk factors and preventions of breast cancer. International Journal of Biological Sciences, 13(11), 1387\u20131397. https:\/\/doi.org\/10.7150\/ijbs.21635","journal-title":"International Journal of Biological Sciences"},{"issue":"11","key":"10059_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/BCTT.S176070","volume":"10","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed, Z., & Salehiniya, H. (2019). Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press), 10(11), 151\u2013164. https:\/\/doi.org\/10.2147\/BCTT.S176070. PMID:31040712;PMCID:PMC6462164.","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10059_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.4103\/1119-3077.156905","volume":"18","author":"CC Nwafor","year":"2015","unstructured":"Nwafor, C. C., & Keshinro, S. O. (2015). Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience. Niger Journal of Clinical Practice, 18, 553\u2013558.","journal-title":"Niger Journal of Clinical Practice"},{"issue":"4","key":"10059_CR6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000488382","volume":"62","author":"R Nishimura","year":"2018","unstructured":"Nishimura, R., Murata, Y., Mori, K., Yamashiro, K., Kuraoka, K., Ichihara, S., Taguchi, K., Suzuki, H., Ito, M., & Yamashita, N. (2018). Evaluation of the HER2 and hormone receptor status in metastatic breast cancer using cell blocks: A multi-institutional study. Acta Cytologica, 62(4), 288\u2013294. https:\/\/doi.org\/10.1159\/000488382","journal-title":"Acta Cytologica"},{"issue":"2","key":"10059_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-012-2289-9","volume":"136","author":"H Masuda","year":"2012","unstructured":"Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012). Role of epidermal growth factor receptor in breast cancer. Breast Cancer Research and Treatment, 136(2), 331\u2013345. https:\/\/doi.org\/10.1007\/s10549-012-2289-9","journal-title":"Breast Cancer Research and Treatment"},{"key":"10059_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10549-020-05608-3","volume":"181","author":"A Bhattacharjee","year":"2020","unstructured":"Bhattacharjee, A., Rajendra, J., Dikshit, R., et al. (2020). HER2 borderline is a negative prognostic factor for primary malignant breast cancer. Breast Cancer Research and Treatment, 181, 225\u2013231. https:\/\/doi.org\/10.1007\/s10549-020-05608-3","journal-title":"Breast Cancer Research and Treatment"},{"issue":"Suppl 1","key":"10059_CR9","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/annonc\/12.suppl_1.s23","volume":"12","author":"T Cooke","year":"2001","unstructured":"Cooke, T., Reeves, J., Lanigan, A., & Stanton, P. (2001). HER2 as a prognostic and predictive marker for breast cancer. Annals of Oncology, 12(Suppl 1), S23\u2013S28. https:\/\/doi.org\/10.1093\/annonc\/12.suppl_1.s23. PMID: 11521717.","journal-title":"Annals of Oncology"},{"key":"10059_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2147\/BCTT.S288344","volume":"13","author":"MA Salkeni","year":"2021","unstructured":"Salkeni, M. A., Rizvi, W., Hein, K., & Higa, G. M. (2021). Neu perspectives, therapies, and challenges for metastatic HER2-positive breast cancer. Breast Cancer (Dove Med Press)., 13, 539\u2013557. https:\/\/doi.org\/10.2147\/BCTT.S288344","journal-title":"Breast Cancer (Dove Med Press)."},{"issue":"1","key":"10059_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41523-021-00265-1.PMID:34016991;PMCID:PMC8137941","volume":"7","author":"I Schlam","year":"2021","unstructured":"Schlam, I., & Swain, S. M. (2021). HER2-positive breast cancer and tyrosine kinase inhibitors: The time is now. Npj Breast Cancer, 7(1), 56. https:\/\/doi.org\/10.1038\/s41523-021-00265-1.PMID:34016991;PMCID:PMC8137941","journal-title":"Npj Breast Cancer"},{"issue":"1","key":"10059_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0069-2","volume":"4","author":"J Wang","year":"2019","unstructured":"Wang, J., & Xu, B. (2019). Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduction and Targeted Therapy, 4(1), Article 34. https:\/\/doi.org\/10.1038\/s41392-019-0069-2","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"2","key":"10059_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1586\/era.10.226","volume":"11","author":"D Gajria","year":"2011","unstructured":"Gajria, D., & Chandarlapaty, S. (2011). HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert Review of Anticancer Therapy, 11(2), 263\u2013275. https:\/\/doi.org\/10.1586\/era.10.226","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"2","key":"10059_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2217\/17455057.5.2.135","volume":"5","author":"B Haq","year":"2009","unstructured":"Haq, B., & Geyer, C. E. (2009). Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer. Women\u2019s Health, 5(2), 135\u2013147. https:\/\/doi.org\/10.2217\/17455057.5.2.135","journal-title":"Women\u2019s Health"},{"key":"10059_CR15","volume-title":"Trastuzumab","author":"K Greenblatt","year":"2022","unstructured":"Greenblatt, K., & Khaddour, K. (2022). Trastuzumab. Treasure Island (FL): StatPearls Publishing."},{"key":"10059_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40164-017-0091-4","volume":"6","author":"S Yu","year":"2017","unstructured":"Yu, S., Liu, Q., Han, X., et al. (2017). Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Experimental Hematology & Oncology, 6, 31. https:\/\/doi.org\/10.1186\/s40164-017-0091-4","journal-title":"Experimental Hematology & Oncology"},{"issue":"11","key":"10059_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine, 344(11), 783\u2013792. https:\/\/doi.org\/10.1056\/NEJM200103153441101","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10059_CR18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1358\/dot.1999.35.12.564040","volume":"35","author":"J Albanell","year":"1999","unstructured":"Albanell, J., & Baselga, J. (1999). Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs of Today (Barcelona, Spain), 35(12), 931\u2013946. PMID: 12973420.","journal-title":"Drugs of Today (Barcelona, Spain)"},{"issue":"2","key":"10059_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1586\/era.10.226","volume":"11","author":"D Gajria","year":"2011","unstructured":"Gajria, D., & Chandarlapaty, S. (2011). HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert Review of Anticancer Therapy, 11(2), 263\u2013275. https:\/\/doi.org\/10.1586\/era.10.226","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"12","key":"10059_CR20","first-page":"4892","volume":"61","author":"M Cuello","year":"2001","unstructured":"Cuello, M., Ettenberg, S. A., Clark, A. S., Keane, M. M., Posner, R. H., Nau, M. M., Dennis, P. A., & Lipkowitz, S. (2001). Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Research, 61(12), 4892\u20134900.","journal-title":"Cancer Research"},{"issue":"3","key":"10059_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11523-015-0409-2","volume":"11","author":"SC Sodergren","year":"2016","unstructured":"Sodergren, S. C., Copson, E., White, A., Efficace, F., Sprangers, M., Fitzsimmons, D., Bottomley, A., & Johnson, C. D. (2016). Systematic review of the side effects associated with anti-HER2-targeted therapies used in the treatment of breast cancer, on behalf of the EORTC Quality of Life Group. Targeted Oncology, 11(3), 277\u2013292. https:\/\/doi.org\/10.1007\/s11523-015-0409-2","journal-title":"Targeted Oncology"},{"issue":"8","key":"10059_CR22","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1185\/03007995.2013.807232","volume":"29","author":"MA Sendur","year":"2013","unstructured":"Sendur, M. A., Aksoy, S., & Altundag, K. (2013). Cardiotoxicity of novel HER2-targeted therapies. Current Medical Research and Opinion, 29(8), 1015\u20131024. https:\/\/doi.org\/10.1185\/03007995.2013.807232","journal-title":"Current Medical Research and Opinion"},{"key":"10059_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01114-x","author":"SF Dent","year":"2021","unstructured":"Dent, S. F., Morse, A., Burnette, S., Guha, A., & Moore, H. (2021). Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer. Current Oncology Reports. https:\/\/doi.org\/10.1007\/s11912-021-01114-x","journal-title":"Current Oncology Reports"},{"issue":"1","key":"10059_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","volume":"188","author":"N Dempsey","year":"2021","unstructured":"Dempsey, N., Rosenthal, A., Dabas, N., Kropotova, Y., Lippman, M., & Bishopric, N. H. (2021). Trastuzumab-induced cardiotoxicity: A review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Research and Treatment, 188(1), 21\u201336. https:\/\/doi.org\/10.1007\/s10549-021-06280-x. 2021 Jun 11. PMID: 34115243.","journal-title":"Breast Cancer Research and Treatment"},{"issue":"2","key":"10059_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/jnci\/djaa096","volume":"113","author":"C Ramin","year":"2021","unstructured":"Ramin, C., Schaeffer, M. L., Zheng, Z., Connor, A. E., Judith Hoffman-Bolton, A. A., Lau, B., & Visvanathan, K. (2021). All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort. JNCI: Journal of the National Cancer Institute, 113(2), 137\u2013145. https:\/\/doi.org\/10.1093\/jnci\/djaa096","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"7","key":"10059_CR26","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/cncr.10854.Erratum.In:Cancer.2003Feb15;97(4):1136","volume":"95","author":"DL Keefe","year":"2002","unstructured":"Keefe, D. L. (2002). Trastuzumab-associated cardiotoxicity. Cancer, 95(7), 1592\u20131600. https:\/\/doi.org\/10.1002\/cncr.10854.Erratum.In:Cancer.2003Feb15;97(4):1136. PMID: 12237930.","journal-title":"Cancer"},{"issue":"5","key":"10059_CR27","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1007\/s12032-012-0291-z","volume":"29","author":"O Tanriverdi","year":"2012","unstructured":"Tanriverdi, O., Meydan, N., & Barutca, S. (2012). Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: A pilot study. Medical Oncology, 29(5), 3265\u20133271. https:\/\/doi.org\/10.1007\/s12032-012-0291-z","journal-title":"Medical Oncology"},{"issue":"39","key":"10059_CR28","doi-asserted-by":"publisher","first-page":"25738","DOI":"10.18632\/oncotarget.25008","volume":"9","author":"J Duan","year":"2018","unstructured":"Duan, J., Tao, J., Zhai, M., Li, C., Zhou, N., Lv, J., Wang, L., Lin, L., & Bai, R. (2018). Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: Current evidence and future research perspectives. Oncotarget, 9(39), 25738\u201325749. https:\/\/doi.org\/10.18632\/oncotarget.25008","journal-title":"Oncotarget"},{"issue":"5 Suppl 16","key":"10059_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/j.seminoncol.2003.08.007","volume":"30","author":"PM Klein","year":"2003","unstructured":"Klein, P. M., & Dybdal, N. (2003). Trastuzumab and cardiac dysfunction: Update on preclinical studies. Seminars in Oncology, 30(5 Suppl 16), 49\u201353. https:\/\/doi.org\/10.1053\/j.seminoncol.2003.08.007. PMID: 14613026.","journal-title":"Seminars in Oncology"},{"issue":"5","key":"10059_CR30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00424-013-1247-7","volume":"465","author":"PA Arias-Loza","year":"2013","unstructured":"Arias-Loza, P. A., Muehlfelder, M., & Pelzer, T. (2013). Estrogen and estrogen receptors in cardiovascular oxidative stress. Pfl\u00fcgers Archiv\u202f: European Journal of Physiology, 465(5), 739\u2013746. https:\/\/doi.org\/10.1007\/s00424-013-1247-7. 2013 Feb 17. PMID: 23417608.","journal-title":"Pfl\u00fcgers Archiv : European Journal of Physiology"},{"issue":"1","key":"10059_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-017-0152-8","volume":"8","author":"A Iorga","year":"2017","unstructured":"Iorga, A., Cunningham, C. M., Moazeni, S., Ruffenach, G., Umar, S., & Eghbali, M. (2017). The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biology of Sex Differences, 8(1), Article 33. https:\/\/doi.org\/10.1186\/s13293-017-0152-8","journal-title":"Biology of Sex Differences"},{"issue":"6","key":"10059_CR32","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","volume":"15","author":"N Mohan","year":"2016","unstructured":"Mohan, N., Shen, Y., Endo, Y., ElZarrad, M. K., & Wu, W. J. (2016). Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Molecular Cancer Therapeutics, 15(6), 1321\u20131331.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"16","key":"10059_CR33","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England Journal of Medicine, 353(16), 1659\u20131672. https:\/\/doi.org\/10.1056\/NEJMoa052306","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10059_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.4143\/crt.2018.262","volume":"51","author":"EK Kim","year":"2019","unstructured":"Kim, E. K., Cho, J., Kim, J. Y., Chang, S. A., Park, S. J., Choi, J. O., et al. (2019). Early decline in left ventricular ejection fraction can predict trastuzumab-related cardiotoxicity in patients with breast cancer: A study using 13 years of registry data. Cancer Research and Treatment, 51(2), 727\u2013736. https:\/\/doi.org\/10.4143\/crt.2018.262","journal-title":"Cancer Research and Treatment"},{"issue":"12","key":"10059_CR35","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., et al. (2020). Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. Journal of Clinical Oncology, 38(12), 1346\u20131366. https:\/\/doi.org\/10.1200\/JCO.19.02309","journal-title":"Journal of Clinical Oncology"},{"key":"10059_CR36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1136\/heart.88.6.559","volume":"88","author":"JE Otterstad","year":"2002","unstructured":"Otterstad, J. E. (2002). Measuring left ventricular volume and ejection fraction with the biplane Simpson\u2019s method. Heart, 88, 559\u2013560.","journal-title":"Heart"},{"issue":"1","key":"10059_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/anec.12804","volume":"26","author":"P Dahlberg","year":"2021","unstructured":"Dahlberg, P., Diamant, U. B., Gilljam, T., Rydberg, A., & Bergfeldt, L. (2021). QT correction using Bazett\u2019s formula remains preferable in long QT syndrome type 1 and 2. Annals of Noninvasive Electrocardiology, 26(1), Article e12804. https:\/\/doi.org\/10.1111\/anec.12804","journal-title":"Annals of Noninvasive Electrocardiology"},{"key":"10059_CR38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","volume":"31","author":"SM Ewer","year":"2008","unstructured":"Ewer, S. M., & Ewer, M. S. (2008). Cardiotoxicity profile of trastuzumab. Drug Safety, 31, 459.","journal-title":"Drug Safety"},{"key":"10059_CR39","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/jnci\/djs317","volume":"104","author":"EJ Bowels","year":"2012","unstructured":"Bowels, E. J., Wellman, R., Feigelson, H. S., et al. (2012). Risk of heart failure in breast cancer patients after anthracycline and tratuzuab treatment: A retrospective cohort study. Journal of the National Cancer Institute, 104, 1293. https:\/\/doi.org\/10.1093\/jnci\/djs317","journal-title":"Journal of the National Cancer Institute"},{"issue":"7","key":"10059_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"18","author":"D Cardinale","year":"2020","unstructured":"Cardinale, D., Lacopo, W., Cipolla, C., et al. (2020). Cardiotoxicity of Anthracycline. Frontiers in Cardiovascular Medicine, 18(7), 26. https:\/\/doi.org\/10.3389\/fcvm.2020.00026","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"1","key":"10059_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/abt\/tby003","volume":"1","author":"N Mohan","year":"2018","unstructured":"Mohan, N., Jiang, J., Dokmanovic, M., et al. (2018). Trastuzumab-mediated cardiotoxicity: Current understanding, challenges, and frontiers. Antibody Therapeutics, 1(1), 13\u201317. https:\/\/doi.org\/10.1093\/abt\/tby003","journal-title":"Antibody Therapeutics"},{"key":"10059_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s43044-023-00331-y","volume":"75","author":"R Levicki","year":"2023","unstructured":"Levicki, R., Bencic, M., Vranesic, I., et al. (2023). Effects of Trastuzumab and Trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer. The Egyptian Heart Journal, 75, 11. https:\/\/doi.org\/10.1186\/s43044-023-00331-y","journal-title":"The Egyptian Heart Journal"},{"key":"10059_CR43","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00280-014-2603-9","volume":"74","author":"Xu Na","year":"2014","unstructured":"Na, Xu., Redfern, C., Gordon, M., et al. (2014). Trastuzumab in combination with carboplatine and docetaxel, doesn\u2019t prolong the Qt interval of patients with HER-2 positive metastatic or locally advanced inoperabe solid tumors: Results from a phase Ib study. Cancer Chemotherapy and Pharmacology, 74, 1251\u20131260.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10059_CR44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/s10025-7125(05)70318-7","volume":"85","author":"R Passman","year":"2001","unstructured":"Passman, R., & Kadish, A. (2001). Polymorphic ventricular tachycardia, Long Qt syndrom, and torsades de pointes. Medical Clinics of North America, 85, 321\u2013341. https:\/\/doi.org\/10.1016\/s10025-7125(05)70318-7","journal-title":"Medical Clinics of North America"},{"issue":"5","key":"10059_CR45","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/00005344-200111000-00010","volume":"38","author":"T Yang","year":"2001","unstructured":"Yang, T., Snyders, D., Roden, D. M., et al. (2001). Drug block of I(kr): Model systems and relevance to human arrhythmias. Journal of Cardiovascular Pharmacology, 38(5), 737\u2013744.","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"5","key":"10059_CR46","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1042\/cs0980603","volume":"98","author":"PP Davey","year":"2000","unstructured":"Davey, P. P., Barlow, C., & Hart, G. (2000). Prolongation of the QT interval in heart failure occurs at low but not at high heart rates. Clinical Science (London), 98(5), 603\u2013610.","journal-title":"Clinical Science (London)"},{"key":"10059_CR47","first-page":"336","volume":"11","author":"PM Kolo","year":"2008","unstructured":"Kolo, P. M., Opadijo, O. G., Omotoso, A. B. O., et al. (2008). Prognostic signifigance of QT interval prolongation in adult Nigerians with chronic heart Failure. Nigerian Journal of Clinical Practice., 11, 336\u2013341.","journal-title":"Nigerian Journal of Clinical Practice."},{"key":"10059_CR48","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5114\/wo.2013.34624","volume":"2","author":"J Hunzo","year":"2013","unstructured":"Hunzo, J., Les, D., Sarzczny-Slota, D., et al. (2013). Cardiac side effects of Trastuzumab in breast cancer patients single center experiences. Wspolczesna Onkol, 2, 190\u2013195.","journal-title":"Wspolczesna Onkol"},{"issue":"3","key":"10059_CR49","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1172\/JCI27987","volume":"116","author":"B Deroo","year":"2006","unstructured":"Deroo, B., Korach, K., et al. (2006). Estrogen receptors and human disease. The Journal of Clinical Investigation, 116(3), 561\u201370. https:\/\/doi.org\/10.1172\/JCI27987","journal-title":"The Journal of Clinical Investigation"},{"key":"10059_CR50","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman, A., Hudis, C., Pierri, M. K., et al. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology, 20, 1215\u20131221.","journal-title":"Journal of Clinical Oncology"},{"key":"10059_CR51","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri, V., Lenihan, D. J., Valero, V., et al. (2006). Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D Anderson Cancer Center experience. Journal of Clinical Oncology, 24, 4107\u20134115.","journal-title":"Journal of Clinical Oncology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10059-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-025-10059-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10059-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:12:17Z","timestamp":1760141537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-025-10059-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10059"],"URL":"https:\/\/doi.org\/10.1007\/s12012-025-10059-7","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the institutional review board at the faculty of medicine of Damascus University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}